XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets Statement - USD ($)
$ in Thousands
Jun. 30, 2018
Dec. 31, 2017
CURRENT ASSETS:    
Cash and cash equivalents $ 13,021 $ 14,400
Accounts receivable, net of allowance for doubtful accounts of $2,474 and $2,590 at 2018 and 2017, respectively 136,148 133,097
Inventories 39,855 33,317
Prepaid expenses 13,967 12,592
Income taxes receivable 11,899 7,508
Other current assets 10,772 6,513
TOTAL CURRENT ASSETS 225,662 207,427
PROPERTY, PLANT AND EQUIPMENT, net 122,787 123,098
INTANGIBLES, net 9,786 9,396
GOODWILL 178,129 179,044
DEFERRED TAX ASSETS 11,498 10,719
OTHER ASSETS 56,882 55,128
TOTAL ASSETS 604,744 584,812
CURRENT LIABILITIES:    
Accounts payable 45,278 41,697
Accrued payroll and related costs 21,427 28,887
Taxes other than payroll and income 6,986 7,313
Unearned revenue 12,608 12,627
Income taxes payable 1,167 825
Other current liabilities 13,125 9,227
TOTAL CURRENT LIABILITIES 100,591 100,576
LONG-TERM DEBT, net 241,687 226,989
CONTRACT LIABILITIES 4,664 4,442
DEFERRED COMPENSATION 54,634 52,786
DEFERRED TAX LIABILITIES 6,471 5,323
OTHER LONG-TERM LIABILITIES 38,923 45,964
COMMITMENTS AND CONTINGENCIES (Note 8)
Preference shares, EUR 0.02 par value; 6,000,000 shares authorized, none issued or outstanding 0 0
Common shares, EUR 0.02 par value; 200,000,000 shares authorized, 44,796,252 issued and 44,203,536 outstanding at 2018 and 44,796,252 issued and 44,184,205 outstanding at 2017 1,148 1,148
Additional paid-in capital 58,927 54,463
Retained earnings 173,499 173,855
Accumulated other comprehensive income (loss) (7,490) (8,353)
Treasury shares (at cost), 592,716 at 2018 and 612,047 at 2017 (72,301) (76,269)
Total Core Laboratories N.V. shareholders' equity 153,783 144,844
Non-controlling interest 3,991 3,888
TOTAL EQUITY 157,774 148,732
TOTAL LIABILITIES AND EQUITY $ 604,744 $ 584,812